NDA 019615 · Baxter Hlthcare
Dopamine Hydrochloride In Dextrose 5% In Plastic Container
Dopamine Hydrochloride · Injection
Last checked: Nov 20, 2026Latest source record: Dec 11, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Mar 27, 1987
Approved uses
2
Original approval plus efficacy supplements
Registered trials
586
103 Phase 3, 70 recruiting
FAERS reports
768
730 serious, 321 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 18, 2025.
INDICATIONS AND USAGE Dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in congestive failure. Where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. Patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function and blood pressure have not undergone profound deterioration. Reports indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis. Poor Perfusion of Vital Organs Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or comatose condition. Loss of pallor, increase in toe temperature and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Reported studies indicate that when dopamine hydrochloride is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine hydrochloride has resulted in an increase in urine flow which in some cases reached normal levels. Dopamine hydrochloride may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 17, 2001 Supplement 12 · Efficacy LetterReview
- Mar 27, 1987 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
- DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 320MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 80MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 640MG/100ML · INJECTABLE, INJECTION · Prescription
- DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 160MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dopamine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Diagnosis of PheochromocytomaRecruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00004847 · 3,000 participants (planned) · Start Mar 22, 2000 · Primary completion Nov 30, 2048
Drug: ([18F]-DOPA); ([18F]-6F-DA) · For: Pheochromocytoma; Endocrine Disease; Endocrine Diseases
Sites: Bethesda, Maryland
- Target Hemodynamics and Brain Injury During General Anesthesia in the ElderlyPivotal-lookingSuspended
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
NCT02428062 · 1,812 participants (planned) · Start Oct 2014 · Primary completion Dec 2018
Drug: Phenylephrine; Intravenous fluids and 4 more · For: Post-operative Cognitive Dysfunction
Sites: Milan, Italy
- Dopamine and Norepinephrine in Shock PatientsPivotal-lookingCompleted
Sepsis Occurrence in Acutely Ill PatientsAcademic, hospital or other
NCT00314704 · 1,679 participants · Start Dec 2003 · Primary completion Oct 2007
Drug: dopamine versus norepinephrine · For: Shock
Sites: Vienna, Austria; Brussels, Belgium; Charleroi, Belgium · 8 sites in all
- Platform Adaptive Embedded Trial for Acute Respiratory Distress SyndromePivotal-lookingStatus unknown
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05658692 · 1,000 participants (planned) · Start Oct 1, 2022 · Primary completion Oct 2023
Drug: glucocorticoid therapy; Thymosin Alpha and 5 more · For: Acute Respiratory Distress Syndrome
Sites: Beijing, China; Chengdu, China; Guangdong, China · 11 sites in all
Ken Marek, MDAcademic, hospital or other
NCT01141023 · 952 participants · Start Jun 2010 · Primary completion Jun 30, 2020
Drug: DaTscan · For: Parkinson Disease
Sites: Birmingham, Alabama; Sun City, Arizona; La Jolla, California · 34 sites in all
- PRolaCT - Three Prolactinoma RCTsPivotal-lookingStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04107480 · 880 participants (planned) · Start Jun 21, 2019 · Primary completion Mar 31, 2024
Drug: Dopamine Agonists · For: Prolactinoma; Prolactin-Producing Pituitary Tumor
Sites: Amsterdam-Zuidoost, Netherlands; Delft, Netherlands; Leiden, Netherlands
- Open-Label Safety Study of AXS-05 in Subjects With DepressionPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04039022 · 876 participants · Start Jul 8, 2019 · Primary completion Oct 23, 2020
Drug: AXS-05 (dextromethorphan and bupropion) oral tablets · For: Major Depressive Disorder; Treatment Resistant Depression; Depression
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 51 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective52
- hypotension51
- platelet count decreased46
- pneumonia46
- pyrexia44
- renal impairment42
- blood pressure decreased38
- condition aggravated38
- sepsis37
- cardiac failure36
- cardiac arrest35
- renal failure35
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 54 |
| 2005 | 9 |
| 2006 | 12 |
| 2007 | 22 |
| 2008 | 38 |
| 2009 | 32 |
| 2010 | 42 |
| 2011 | 45 |
| 2012 | 39 |
| 2013 | 38 |
| 2014 | 28 |
| 2015 | 38 |
| 2016 | 40 |
| 2017 | 25 |
| 2018 | 31 |
| 2019 | 37 |
| 2020 | 26 |
| 2021 | 48 |
| 2022 | 48 |
| 2023 | 32 |
| 2024 | 37 |
| 2025 | 30 |
| 2026 | 14 |
Recalls
1 FDA enforcement reports for this application.
Sep 29, 2014 · Class II · Terminated
Lack of Assurance of Sterility: A small cut in the solution bag may have been introduced during the manufacturing process, resulting in a leak of the bag into the overpouch.
Shortages
FDA's drug shortage list.
Current · updated Nov 3, 2026
Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03). Demand increase for the drug
Current · updated Nov 18, 2026
Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02).
Current · updated Nov 18, 2026
Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03).
Current · updated Nov 18, 2026
Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis.
Feber L, Peter NL, Chiocchia V, et al. · JAMA Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Comparison of dopamine and norepinephrine in the treatment of shock.
De Backer D, Biston P, Devriendt J, et al. · N Engl J Med 2010 · Comparative Study, Multicenter Study
- Cortisol decreases and serotonin and dopamine increase following massage therapy.
Field T, Hernandez-Reif M, Diego M, et al. · Int J Neurosci 2005 · Clinical Trial, Randomized Controlled Trial
- Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases.
Schneider-Thoma J, Zhu Y, Qin M, et al. · Lancet 2026 · Comparative Study, Network Meta-Analysis
- THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.
Jia L, Wang P, Li C, et al. · Shock 2023 · Systematic Review, Network Meta-Analysis
- Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
Sacheli MA, Neva JL, Lakhani B, et al. · Mov Disord 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.